Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism
Clin. transl. oncol. (Print)
; 24(11): 2231-2240, noviembre 2022. graf
Article
in En
| IBECS
| ID: ibc-210151
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Although lorlatinib, the third generation of echinoderm microtubule protein 4-anaplastic lymphoma kinase (EML4-ALK) tyrosine kinase inhibitor (TKI), overcame the previous generation ALK-TKIs drug resistance problems, but the mechanism of lorlatinib resistance remained unclear. Furthermore, optimal chemotherapy for lorlatinib-resistant non-small cell lung cancer (NSCLC) patients was still unknown.MethodsA lorlatinib-resistant NSCLC cell line SNU-2535LR was generated by gradually increasing dose of lorlatinib to crizotinib-resistant cell line SNU-2535 in vitro. To study the resistance mechanism of SNU-2535LR cells, we applied CCK-8 assay to detect the sensitivity of crizotinib and the reverse effect of APR-246, a p53 activator, on lorlatinib-induced resistance and different chemotherapy drugs to SNU-2535LR cells. We also detected the expressions of EML4-ALK-related proteins of SNU-2535LR cells via western blot.Please confirm that author names have been identified correctly and are presented in the right order. (AU)
Key words
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Drug Resistance
/
Cisplatin
/
Paclitaxel
/
Docetaxel
/
Crizotinib
/
Aminopyridines
Limits:
Humans
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2022
Document type:
Article